Inspire Sleep Apnea: How It Works, Cost & Results

How Inspire Works: The Hypoglossal Nerve Stimulation Mechanism

Inspire consists of three implanted components: a stimulation lead placed on the hypoglossal nerve (below the jaw), a sensing lead between two ribs that detects respiratory effort, and a small pulse generator implanted under the skin below the collarbone. The system works continuously during sleep: as the sensing lead detects each inhalation, the pulse generator triggers a mild electrical stimulation through the hypoglossal nerve, causing the tongue and upper airway muscles to tense and move anteriorly — clearing the airway obstruction that causes apnea events.

A key non-obvious point: Inspire only works for obstructive sleep apnea, where the airway physically collapses or is blocked. It does not help central sleep apnea, where the brain fails to send the signal to breathe. For OSA patients with a significant retropalatal or retroglossal obstruction (the most common anatomy), hypoglossal stimulation is directly addressing the obstruction mechanism — unlike positional therapy or oral appliances, which work more indirectly.

STAR Trial Results and Real-World Outcomes

The pivotal STAR (Stimulation Therapy for Apnea Reduction) trial, published in The New England Journal of Medicine (Strollo et al., 2014, n = 126), established the clinical foundation for Inspire. At 12 months: median AHI decreased 68% (from 29.3 to 9.0 events/hour); 66% of participants achieved a ≥50% reduction in AHI plus AHI below 20 (the primary responder definition); median Epworth Sleepiness Score improved by 5.1 points.

Five-year follow-up data (Woodson et al., Otolaryngology — Head and Neck Surgery, 2018) confirmed durability: 84% of 5-year completers maintained response. Post-market surveillance data from real-world Inspire implants (n = 2,687, Heiser et al., The Laryngoscope, 2021) showed 75% response rate — slightly lower than the RCT due to wider patient selection, but still strongly positive. Device-related adverse events were uncommon: tongue weakness (14%, typically temporary), discomfort at the stimulation lead site (9%), and infection requiring device removal (< 2%).

Who Qualifies for Inspire: Candidacy Criteria

Inspire candidacy is specific. Not every CPAP-intolerant OSA patient qualifies, and the criteria reflect the anatomy required for hypoglossal stimulation to work.

• Age: 22 or older (FDA approval)
• OSA severity: moderate to severe (AHI 15–65 events/hour); too mild doesn't meet coverage criteria; too severe (AHI > 65) may indicate anatomy less likely to respond
• BMI: less than 32 kg/m² for Medicare; most commercial insurers use ≤ 35. Higher BMI is associated with lower response rates due to increased parapharyngeal fat pad involvement.
• CPAP failure: documented inability to use CPAP adequately (most insurers require a prior CPAP trial)
• Anatomic screen (drug-induced sleep endoscopy): most Inspire programs require a DISE procedure to confirm the obstruction pattern is "concentric" (favorable) vs. "complete circumferential collapse" (unfavorable); approximately 20% of candidates are excluded at this step
• No central or predominant central apnea

The Inspire Procedure: Surgery, Recovery, and Activation

Inspire implantation is typically an outpatient surgery performed under general anesthesia, lasting 2–3 hours. Three small incisions are made: below the jaw (stimulation lead), on the upper chest/neck (sensing lead), and below the collarbone (pulse generator). Most patients go home the same day and return to normal activity within 1–2 weeks.

The device is activated 4–6 weeks after surgery to allow healing, then titrated over 1–2 months through in-office adjustments and home use. Patients use the remote to turn the device on before sleep and off on waking. Some patients also use a patient titration feature (available on the Inspire 5 system) to adjust stimulation amplitude at home within prescribed limits.

Cost and Insurance Coverage for Inspire

Inspire therapy has an estimated device cost of $30,000–$40,000 before professional fees and facility costs; total procedural costs typically run $40,000–$60,000. Insurance coverage has expanded significantly since the initial 2014 FDA approval.

Medicare: covers Inspire for patients meeting candidacy criteria under a specific NCD (National Coverage Determination) issued in 2022. Requirements include confirmed OSA (AHI 15–65), BMI ≤ 32, documented CPAP intolerance, and DISE confirmation. The procedure must be performed at an approved facility.

Commercial insurers: most major commercial plans now cover Inspire, though criteria vary slightly by payer. BCBS, Aetna, Cigna, and United Healthcare all have coverage policies; prior authorization is required universally. Patients typically owe deductible + coinsurance; for those who have met their annual deductible, out-of-pocket cost is often $2,000–$8,000.

Inspire Medical Systems offers a patient assistance program and financial counseling line: their website (inspiresleep.com) has a coverage check tool. See our sleep apnea treatments comparison for cost vs. CPAP, oral appliances, and surgical alternatives.